Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shirley Paski is active.

Publication


Featured researches published by Shirley Paski.


Gastrointestinal Endoscopy Clinics of North America | 2009

Small bowel tumors.

Shirley Paski; Carol E. Semrad

Although rare, small bowel tumors may cause significant morbidity and mortality if left undetected. New endoscopic modalities allow full examination of the small bowel with improved diagnosis. However, isolated mass lesions may be missed by capsule endoscopy or incomplete balloon-assisted enteroscopy. Therefore the use of radiologic imaging and intraoperative enteroscopy for diagnosis should not be forgotten. Endoscopic resection of small bowel polyps and certain vascular tumors is possible but requires proper training. Advances in endoscopic tools are likely to broaden the endoscopic management of small bowel tumors. This article describes the general features of small bowel tumors, clinical presentation, and diagnostic tests followed by a description of the more common tumor types and their management.


American Journal of Physiology-gastrointestinal and Liver Physiology | 2012

Expression of TNFAIP3 in intestinal epithelial cells protects from DSS- but not TNBS-induced colitis

Lesley Rhee; Stephen F. Murphy; Lauren Kolodziej; Wesley Grimm; Christopher R. Weber; James P. Lodolce; Jonathan E. Chang; Sarah Bartulis; Jeannette S. Messer; Jeffery R Schneider; Shirley Paski; Thomas M. Nero; David L. Boone

Intestinal epithelial cells (IEC) maintain gastrointestinal homeostasis by providing a physical and functional barrier between the intestinal lumen and underlying mucosal immune system. The activation of NF-κB and prevention of apoptosis in IEC are required to maintain the intestinal barrier and prevent colitis. How NF-κB activation in IEC prevents colitis is not fully understood. TNFα-induced protein 3 (TNFAIP3) is a NF-κB-induced gene that acts in a negative-feedback loop to inhibit NF-κB activation and also to inhibit apoptosis; therefore, we investigated whether TNFAIP3 expression in the intestinal epithelium impacts susceptibility of mice to colitis. Transgenic mice expressing TNFAIP3 in IEC (villin-TNFAIP3 Tg mice) were exposed to dextran sodium sulfate (DSS) or 2,4,6-trinitrobenzene sulfonic acid (TNBS), and the severity and characteristics of mucosal inflammation and barrier function were compared with wild-type mice. Villin-TNFAIP3 Tg mice were protected from DSS-induced colitis and displayed reduced production of NF-κB-dependent inflammatory cytokines. Villin-TNFAIP3 Tg mice were also protected from DSS-induced increases in intestinal permeability and induction of IEC death. Villin-TNFAIP3 Tg mice were not protected from colitis induced by TNBS. These results indicate that TNFAIP3 expression in IEC prevents colitis involving DSS-induced IEC death, but not colitis driven by T cell-mediated inflammation. As TNFAIP3 inhibits NF-κB activation and IEC death, expression of TNFAIP3 in IEC may provide an avenue to inhibit IEC NF-κB activation without inducing IEC death and inflammation.


Journal of Clinical Gastroenterology | 2016

Obesity and Cardiovascular Risk in Adults With Celiac Disease.

Adam C. Stein; Chuanhong Liao; Shirley Paski; Tamar S. Polonsky; Carol E. Semrad; Sonia S. Kupfer

Background: Patients with celiac disease (CD) may be at an increased risk of cardiovascular disease (CVD), yet CVD risk factors are not well defined in CD. The validated Framingham Heart Study 10-year general CVD risk score (FRS) that incorporates traditional CVD risk factors including body mass index (BMI) has not been previously studied in CD patients. Aims: To compare BMI and FRS in CD patients with population-based controls. Methods: Biopsy-proven CD patients were ascertained retrospectively and data on BMI, systolic blood pressure, hypertension, smoking status, and diabetes were obtained at initial and follow-up visits. FRS was calculated and compared with 4 matched general population non-CD controls from the 2009 to 2010 National Health and Nutrition Examination Survey (NHANES). Results: Of 258 total CD patients, 38.3% were overweight or obese compared with 69.8% of controls (P<0.001). In total, 174 CD patients met the inclusion criteria for FRS calculation. Of these, the median FRS was lower in CD patients compared with controls (3.9 vs. 4.2; P=0.011). In CD patients, tobacco use was significantly lower (P<0.001), whereas systolic blood pressure was significantly higher (P<0.01) than controls. Conclusions: Global CVD risk is lower among patients with CD compared with population controls. Lower BMI and tobacco use among CD patients could account for this difference. These results suggest that factors other than those measured by FRS could contribute to the increased risk of CVD in CD observed in some studies.


Gastroenterology | 2013

Sa1265 Cardiovascular Disease Risk Assessment of Adult Celiac Disease Patients in the Midwestern United States

Adam C. Stein; Rahman Chaudhry; Shirley Paski; NurAlima Grandison; Tamar S. Polonsky; Carol E. Semrad; Sonia S. Kupfer


Gastroenterology | 2012

Mo1806 Gastrokine-1: A Gastric Protein That Protects Mice Against Experimental Colitis

Shirley Paski; Thomas M. Nero; F. Gary Toback; David L. Boone


Gastroenterology | 2018

615 - A VA Cooperative, Randomized Trial of Medical and Surgical Treatments for Patients with Heartburn that is Refractory to Proton Pump Inhibitors

Stuart J. Spechler; Robert H. Lee; Brian R. Smith; Hiroshi Mashimo; Vivian Sanchez; Kerry B. Dunbar; Thai H. Pham; Uma K. Murthy; Taewan Kim; Christian S. Jackson; Jason Wallen; Erik C. von Rosenvinge; Jonathan Pearl; Loren Laine; Anthony W. Kim; Andrew M. Kaz; Roger P. Tatum; Ziad F. Gellad; Sandhya Deenadayalan; Joel H. Rubenstein; Amir Ghaferi; Wai-Kit Lo; Ronald S. Fernando; Bobby S. Chan; Shirley Paski; Dawn Provenzale; Donald O. Castell; David A. Lieberman; Rhonda F. Souza; William D. Chey


Gastroenterology | 2018

444 - Characterization of Conditions Underlying Heartburn Refractory to Proton Pump Inhibitors (PPIS) in a VA Cooperative Study of Medical and Surgical Treatments for PPI-Refractory Heartburn

Stuart J. Spechler; Robert H. Lee; Brian R. Smith; Hiroshi Mashimo; Vivian Sanchez; Kerry B. Dunbar; Thai H. Pham; Uma K. Murthy; Taewan Kim; Christian S. Jackson; Jason Wallen; Erik C. von Rosenvinge; Jonathan Pearl; Loren Laine; Anthony W. Kim; Andrew M. Kaz; Roger P. Tatum; Ziad F. Gellad; Sandhya Deenadayalan; Joel H. Rubenstein; Amir Ghaferi; Wai-Kit Lo; Ronald S. Fernando; Bobby S. Chan; Shirley Paski; Dawn Provenzale; Donald O. Castell; David A. Lieberman; Rhonda F. Souza; William D. Chey


Gastroenterology | 2014

Mo1718 A Secreted Gastric Protein Protects Against NSAID Induced Injury and Colitis

Danika Bakke; Shirley Paski; David L. Boone


Gastroenterology | 2012

Sa1351 HLA DQ Prevalence in DQ2/DQ8 Negative Gluten Sensitivity

Shailaja Jamma; Sonia S. Kupfer; Shirley Paski; Carol E. Semrad


Gastroenterology | 2012

395 High Prevalence of Overweight and Obese Adult Celiac Patients in the Midwestern United States

Sonia S. Kupfer; Shirley Paski; NurAlima Grandison; Carol E. Semrad

Collaboration


Dive into the Shirley Paski's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrew M. Kaz

University of Washington

View shared research outputs
Top Co-Authors

Avatar

Anthony W. Kim

University of Southern California

View shared research outputs
Top Co-Authors

Avatar

Brian R. Smith

University of California

View shared research outputs
Top Co-Authors

Avatar

Christian S. Jackson

Loma Linda University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge